Pharming Net Working Capital vs Net Receivables Analysis

PHAR Stock

USD 10.26 0.07 0.69%

Pharming Group financial indicator trend analysis is much more than just breaking down Pharming Group NV prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pharming Group NV is a good investment. Please check the relationship between Pharming Group Net Working Capital and its Net Receivables accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Net Working Capital vs Net Receivables

Net Working Capital vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pharming Group NV Net Working Capital account and Net Receivables. At this time, the significance of the direction appears to have strong relationship.

The correlation between Pharming Group's Net Working Capital and Net Receivables is 0.69. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Pharming Group NV, assuming nothing else is changed. The correlation between historical values of Pharming Group's Net Working Capital and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Pharming Group NV are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Net Working Capital i.e., Pharming Group's Net Working Capital and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.69

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Working Capital

Net Receivables

Most indicators from Pharming Group's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pharming Group NV current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

At this time, Pharming Group's Selling General Administrative is relatively stable compared to the past year. As of 07/25/2025, Tax Provision is likely to grow to about 3.5 M, while Sales General And Administrative To Revenue is likely to drop 0.24.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	169.8M	225.5M	270.4M	283.9M
Cost Of Revenue	17.6M	25.2M	35.4M	37.2M

Total Operating Expenses Cost Of Revenue

Pharming Group fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.96	0.61	0.72	0.89	0.88	0.22	0.23	0.23	0.43	0.78	0.96	-0.14	0.98	0.69	0.8	0.44	0.92	0.72	0.46	0.85	0.96	0.92	0.12	0.88	-0.36
Short Long Term Debt Total	0.96		0.54	0.66	0.81	0.85	0.14	0.23	0.17	0.31	0.82	0.93	-0.18	0.95	0.59	0.77	0.36	0.98	0.67	0.41	0.8	0.97	0.88	0.09	0.9	-0.37
Other Current Liab	0.61	0.54		0.54	0.77	0.41	0.03	0.49	0.12	0.3	0.34	0.58	-0.1	0.55	0.91	0.45	0.68	0.51	0.85	0.3	0.63	0.59	0.79	0.12	0.54	-0.32
Total Current Liabilities	0.72	0.66	0.54		0.55	0.41	0.48	0.25	-0.21	0.79	0.47	0.85	0.07	0.58	0.61	0.79	0.24	0.54	0.45	0.28	0.77	0.79	0.57	0.75	0.86	-0.44
Total Stockholder Equity	0.89	0.81	0.77	0.55		0.83	0.14	0.31	0.45	0.38	0.66	0.8	-0.12	0.89	0.85	0.63	0.64	0.77	0.87	0.47	0.71	0.78	0.98	-0.07	0.71	-0.27
Property Plant And Equipment Net	0.88	0.85	0.41	0.41	0.83		0.03	0.14	0.36	0.24	0.73	0.78	-0.2	0.9	0.53	0.59	0.4	0.85	0.66	0.37	0.69	0.78	0.83	-0.17	0.66	-0.22
Current Deferred Revenue	0.22	0.14	0.03	0.48	0.14	0.03		-0.34	-0.16	0.71	0.32	0.35	0.04	0.17	0.05	0.34	-0.24	0.04	-0.2	0.01	0.31	0.22	0.08	0.35	0.39	-0.11
Net Debt	0.23	0.23	0.49	0.25	0.31	0.14	-0.34		0.09	0.18	-0.34	0.18	0.17	0.15	0.67	-0.07	0.85	0.22	0.61	0.54	0.18	0.26	0.37	0.08	0.17	-0.11
Retained Earnings	0.23	0.17	0.12	-0.21	0.45	0.36	-0.16	0.09		-0.11	0.13	0.08	0.38	0.3	0.25	-0.11	0.35	0.12	0.34	0.42	-0.25	0.0	0.34	-0.46	0.0	0.43
Accounts Payable	0.43	0.31	0.3	0.79	0.38	0.24	0.71	0.18	-0.11		0.19	0.58	0.25	0.29	0.48	0.49	0.21	0.17	0.23	0.27	0.49	0.44	0.33	0.64	0.59	-0.22
Cash	0.78	0.82	0.34	0.47	0.66	0.73	0.32	-0.34	0.13	0.19		0.78	-0.3	0.82	0.26	0.77	-0.09	0.81	0.36	0.07	0.67	0.77	0.68	0.02	0.76	-0.31
Non Current Assets Total	0.96	0.93	0.58	0.85	0.8	0.78	0.35	0.18	0.08	0.58	0.78		-0.07	0.89	0.65	0.84	0.3	0.86	0.61	0.38	0.86	0.97	0.83	0.36	0.97	-0.37
Non Currrent Assets Other	-0.14	-0.18	-0.1	0.07	-0.12	-0.2	0.04	0.17	0.38	0.25	-0.3	-0.07		-0.2	0.01	-0.36	0.05	-0.27	-0.14	0.5	-0.45	-0.17	-0.19	0.24	-0.04	0.75
Cash And Short Term Investments	0.98	0.95	0.55	0.58	0.89	0.9	0.17	0.15	0.3	0.29	0.82	0.89	-0.2		0.61	0.75	0.42	0.94	0.7	0.46	0.8	0.91	0.92	-0.07	0.8	-0.32
Net Receivables	0.69	0.59	0.91	0.61	0.85	0.53	0.05	0.67	0.25	0.48	0.26	0.65	0.01	0.61		0.46	0.85	0.53	0.91	0.48	0.63	0.63	0.84	0.16	0.58	-0.31
Common Stock Shares Outstanding	0.8	0.77	0.45	0.79	0.63	0.59	0.34	-0.07	-0.11	0.49	0.77	0.84	-0.36	0.75	0.46		0.08	0.7	0.49	0.01	0.85	0.82	0.67	0.43	0.83	-0.69
Short Term Investments	0.44	0.36	0.68	0.24	0.64	0.4	-0.24	0.85	0.35	0.21	-0.09	0.3	0.05	0.42	0.85	0.08		0.36	0.82	0.64	0.34	0.36	0.66	-0.17	0.2	-0.11
Non Current Liabilities Total	0.92	0.98	0.51	0.54	0.77	0.85	0.04	0.22	0.12	0.17	0.81	0.86	-0.27	0.94	0.53	0.7	0.36		0.65	0.4	0.79	0.94	0.86	-0.04	0.82	-0.36
Inventory	0.72	0.67	0.85	0.45	0.87	0.66	-0.2	0.61	0.34	0.23	0.36	0.61	-0.14	0.7	0.91	0.49	0.82	0.65		0.39	0.61	0.65	0.89	-0.05	0.53	-0.37
Other Current Assets	0.46	0.41	0.3	0.28	0.47	0.37	0.01	0.54	0.42	0.27	0.07	0.38	0.5	0.46	0.48	0.01	0.64	0.4	0.39		0.16	0.4	0.48	-0.09	0.31	0.39
Other Stockholder Equity	0.85	0.8	0.63	0.77	0.71	0.69	0.31	0.18	-0.25	0.49	0.67	0.86	-0.45	0.8	0.63	0.85	0.34	0.79	0.61	0.16		0.88	0.77	0.27	0.8	-0.67
Total Liab	0.96	0.97	0.59	0.79	0.78	0.78	0.22	0.26	0.0	0.44	0.77	0.97	-0.17	0.91	0.63	0.82	0.36	0.94	0.65	0.4	0.88		0.85	0.27	0.94	-0.44
Total Current Assets	0.92	0.88	0.79	0.57	0.98	0.83	0.08	0.37	0.34	0.33	0.68	0.83	-0.19	0.92	0.84	0.67	0.66	0.86	0.89	0.48	0.77	0.85		-0.06	0.75	-0.35
Short Term Debt	0.12	0.09	0.12	0.75	-0.07	-0.17	0.35	0.08	-0.46	0.64	0.02	0.36	0.24	-0.07	0.16	0.43	-0.17	-0.04	-0.05	-0.09	0.27	0.27	-0.06		0.46	-0.27
Intangible Assets	0.88	0.9	0.54	0.86	0.71	0.66	0.39	0.17	0.0	0.59	0.76	0.97	-0.04	0.8	0.58	0.83	0.2	0.82	0.53	0.31	0.8	0.94	0.75	0.46		-0.39
Common Stock	-0.36	-0.37	-0.32	-0.44	-0.27	-0.22	-0.11	-0.11	0.43	-0.22	-0.31	-0.37	0.75	-0.32	-0.31	-0.69	-0.11	-0.36	-0.37	0.39	-0.67	-0.44	-0.35	-0.27	-0.39

Click cells to compare fundamentals

Pharming Group Account Relationship Matchups

Pharming Group fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	419.1M	396.9M	425.8M	462.9M	386.9M	202.9M
Short Long Term Debt Total	162.2M	161.6M	166.7M	171.5M	108.4M	71.2M
Other Current Liab	58.8M	32.0M	42.3M	45.5M	106.7M	112.0M
Total Current Liabilities	77.0M	46.7M	59.7M	78.0M	71.2M	48.1M
Total Stockholder Equity	183.7M	192.7M	204.6M	218.8M	214.2M	224.9M
Property Plant And Equipment Net	21.7M	33.1M	39.1M	33.5M	23.3M	15.8M
Current Deferred Revenue	34.6M	34.3M	(44.4K)	(56.2K)	(64.7K)	(61.4K)
Net Debt	(43.3M)	(30.1M)	(40.6M)	109.8M	55.4M	58.1M
Retained Earnings	(317.5M)	(269.4M)	(256.4M)	(265.3M)	(265.4M)	(278.6M)
Accounts Payable	13.5M	5.1M	6.1M	16.0M	10.1M	10.3M
Cash	205.5M	191.7M	207.3M	61.7M	53.0M	71.0M
Non Current Assets Total	155.5M	147.7M	148.3M	146.5M	121.5M	76.2M
Non Currrent Assets Other	510.4K	(303.4K)	1.3M	1.6M	1.6M	884.4K
Cash And Short Term Investments	205.5M	191.7M	207.3M	213.4M	162.1M	86.0M
Net Receivables	19.2M	15.9M	19.6M	42.6M	50.2M	52.7M
Common Stock Shares Outstanding	85.3M	87.6M	88.4M	65.7M	68.9M	46.6M
Liabilities And Stockholders Equity	419.1M	396.9M	425.8M	462.9M	386.9M	202.9M
Non Current Liabilities Total	158.4M	157.5M	161.5M	166.1M	101.5M	71.7M
Inventory	21.2M	27.3M	42.3M	51.4M	53.8M	56.5M
Other Current Assets	5.0M	2.6M	2.5M	9.7M	4.7M	3.9M
Other Stockholder Equity	500.9M	462.7M	462.3M	479.0M	488.7M	402.3M
Total Liab	235.4M	204.2M	221.2M	244.1M	172.7M	119.8M
Total Current Assets	263.6M	249.2M	277.5M	316.3M	278.4M	292.4M
Short Term Debt	4.0M	2.4M	5.2M	5.4M	6.9M	6.6M
Intangible Assets	94.2M	83.8M	75.1M	71.3M	58.9M	44.2M
Common Stock	7.9M	7.3M	7.5M	7.7M	7.8M	7.4M
Accumulated Other Comprehensive Income	5.3M	2.2M	(8.7M)	(1.9M)	(209K)	(198.6K)
Other Liab	32.7M	17.3M	173K	146K	131.4K	124.8K
Net Tangible Assets	38.2M	77.2M	96.2M	129.5M	148.9M	156.4M
Long Term Debt	121.9M	122.6M	131.6M	136.6M	78.2M	94.4M
Capital Lease Obligations	8.3M	18.4M	33.3M	33.1M	29.9M	17.9M
Deferred Long Term Liab	2.2M	4.3M	4.4M	266K	239.4K	227.4K
Net Invested Capital	273.0M	294.5M	338.0M	357.2M	303.5M	268.1M
Short Long Term Debt	1.7M	1.7M	1.8M	1.8M	4.2M	4.0M
Non Current Liabilities Other	32.0M	17.3M	173K	146K	131.4K	124.8K
Net Working Capital	151.8M	178.8M	217.8M	238.4M	204.6M	145.6M
Property Plant Equipment	14.5M	17.6M	29.3M	39.1M	45.0M	47.3M

Pair Trading with Pharming Group

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pharming Group position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharming Group will appreciate offsetting losses from the drop in the long position's value.

Moving together with Pharming Stock

0.66

Agilent Technologies Earnings Call This Week

Pair Corr

Moving against Pharming Stock

0.77	TOVX	Theriva Biologics	Pair Corr
0.71	CLOV	Clover Health Investments	Pair Corr
0.55	CMND	Clearmind Medicine Common	Pair Corr
0.54	VALN	Valneva SE ADR	Pair Corr
0.52	TELO	Telomir Pharmaceuticals,	Pair Corr

The ability to find closely correlated positions to Pharming Group could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pharming Group when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pharming Group - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pharming Group NV to buy it.

The correlation of Pharming Group is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pharming Group moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pharming Group NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Pharming Group can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC